Newbury Pharmaceuticals

“The addition of Melatonin ER is adding a new partnership with a European producer which can be used to source additional new products. This is our fourth new partnership within a couple of weeks which have in total granted us access to more than 10 new products.” says Mr Lars Minor CEO of Newbury

Regulatory filling of Melatonin ER 2 mg will take place in the near future and launch of this medicine is planned in the Nordics where the total annual value of the market is estimated to be 11 MEUR according to DLMI Nordic Pharma Insights.
 
Melatonin ER is used on its own for the short-term treatment of primary insomnia (poor quality of sleep) in patients aged 55 years or over. Older people may produce less melatonin, leading to the development of insomnia. By replacing the hormone, Melatonin ER increases blood levels of melatonin, helping people to sleep. Because Melatonin ER tablets release melatonin slowly over a few hours, they mimic the natural production of melatonin in the body.